Cargando…

Indacaterol, A Novel Once Daily Inhaled β2-Adrenoreceptor Agonist

In this article we will review the role of long acting β2-adrenoreceptor agonists and long-acting muscarinic agents in the management of airflow obstruction. We will then focus our attention on indacaterol, one of the new once daily inhaled β2-adrenoreceptor agonists. Pharmacologically this drug is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roig, Jorge, Hernando, Rosana, Mora, Ramon
Formato:	Texto
Lenguaje:	English
Publicado:	Bentham Open 2009
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2682927/ https://www.ncbi.nlm.nih.gov/pubmed/19452036 http://dx.doi.org/10.2174/1874306400903010027

Ejemplares similares

Indacaterol: a new once daily long-acting beta(2) adrenoceptor agonist
por: Beeh, Kai M, et al.
Publicado: (2010)

The Beta-2-Adrenoreceptor Agonists, Formoterol and Indacaterol, but Not Salbutamol, Effectively Suppress the Reactivity of Human Neutrophils In Vitro
por: Anderson, Ronald, et al.
Publicado: (2014)

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
por: Roskell, Neil S, et al.
Publicado: (2014)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
por: Vincken, Walter, et al.
Publicado: (2014)

Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β(2)-adrenoreceptor agonist (uLABA)
por: Bjermer, Leif, et al.
Publicado: (2015)

Inhalation of a Short-Acting β(2)-Adrenoreceptor Agonist Induces a Hypercoagulable State in Healthy Subjects
por: Ali-Saleh, Mais, et al.
Publicado: (2016)

Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
por: Mtibaa, Mondher, et al.
Publicado: (2021)

Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data
por: Bleecker, Eugene R, et al.
Publicado: (2011)

Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol
por: Beier, Jutta, et al.
Publicado: (2011)

Mirabegron – a selective β3-adrenoreceptor agonist for the treatment of overactive bladder
por: Bhide, Alka A, et al.
Publicado: (2012)

Eosinophils protect pressure overload- and β-adrenoreceptor agonist-induced cardiac hypertrophy
por: Yang, Chongzhe, et al.
Publicado: (2022)

Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US
por: Rajagopalan, Krithika, et al.
Publicado: (2018)

Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study
por: Feldman, Gregory, et al.
Publicado: (2010)

β-Adrenoreceptor agonists in the management of pain associated with renal colic: a systematic review
por: Tabner, Andrew John, et al.
Publicado: (2016)

A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma
por: Brittain, Dominic, et al.
Publicado: (2022)

The use of β(2)-adrenoreceptor agonists in viral bronchiolitis: scientific rationale beyond evidence-based guidelines
por: Nino, Gustavo, et al.
Publicado: (2020)

The effects of novel α(2)-adrenoreceptor agonist dexmedetomidine on shivering in patients underwent caesarean section
por: Yu, Gaofeng, et al.
Publicado: (2019)

Mirabegron, a β3‑adrenoreceptor agonist, regulates right and left atrial arrhythmogenesis differently
por: Chan, Chao-Shun, et al.
Publicado: (2022)

MRI Assessment of Cardiomyopathy Induced by β1-Adrenoreceptor Autoantibodies and Protection Through β3-Adrenoreceptor Overexpression
por: Vanhoutte, Laetitia, et al.
Publicado: (2017)

Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review
por: Ulrik, Charlotte Suppli
Publicado: (2014)

Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial
por: Beasley, Richard W, et al.
Publicado: (2015)

Medication Adherence and Asthma Control with Once-Daily Indacaterol/Glycopyrronium/Mometasone Furoate Breezhaler Digital Companion: 90-Day Analysis from Germany
por: Woehrle, Holger, et al.
Publicado: (2023)

Efficacy, Safety, and Systemic Exposure of Once-Daily Indacaterol Acetate in Pediatric Asthma: A Randomized, Double-Blind, Controlled Dose-Finding Study
por: Sekerel, Bulent Enis, et al.
Publicado: (2023)

Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers
por: Jiang, Ji, et al.
Publicado: (2014)

Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review
por: Ridolo, Erminia, et al.
Publicado: (2013)

Comparative In Vitro Study of Various α(2)-Adrenoreceptor Agonist Drugs for Ticagrelor Reversal
por: Porta Bonete, Guillaume, et al.
Publicado: (2020)

Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β(2) agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial
por: Busse, William W, et al.
Publicado: (2013)

Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients
por: Miller, David, et al.
Publicado: (2020)

Clinical Utility of β(3)-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations
por: Krhut, Jan, et al.
Publicado: (2022)

A UK-Based Cost-Utility Analysis of Indacaterol, A Once-Daily Maintenance Bronchodilator for Patients with COPD, Using Real World Evidence on Resource Use
por: Price, David, et al.
Publicado: (2013)

Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: A study level and a patient level network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2012)

Randomised trial of once-daily vilanterol in children with asthma on inhaled corticosteroid therapy
por: Oliver, Amanda J., et al.
Publicado: (2016)

Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences
por: Ohno, Takeshi, et al.
Publicado: (2014)

Once-daily indacaterol 75 μg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients’ perceived onset of effect
por: Siler, Thomas M, et al.
Publicado: (2014)

Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease
por: Hataji, Osamu, et al.
Publicado: (2013)

Real-life effectiveness of indacaterol/glycopyrronium/mometasone for symptomatic relief of cough after switching from inhaled corticosteroid/long-acting β(2)-agonist therapy in patients with asthma: REACH study design
por: Niimi, Akio, et al.
Publicado: (2023)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao, Qing, et al.
Publicado: (2016)

Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
por: Ismaila, Afisi S, et al.
Publicado: (2019)

Spotlight on ROS and β3-Adrenoreceptors Fighting in Cancer Cells
por: Calvani, Maura, et al.
Publicado: (2019)

Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD
por: Prakash, Anoop, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jm63i9kgnnsg45ng8dq7rm1npl